Proactol LTD
Bargain WD Online Catalogue - A lot high quality products - Good products, Cheap prices

RSS health news
Easy | Informative | Interesting | Sponsored link | Members | Top authors

Alkermes Announces Results From Phase 2 Study Of ALKS 33 For Treatment Of Binge Eating Disorder

Alkermes, Inc. (NASDAQ: ALKS) today announced topline results from a phase 2 clinical study of ALKS 33 in the treatment of binge eating disorder. This randomized, double-blind, placebo-controlled, 12-week study was designed to assess the safety and efficacy of daily oral administration of ALKS 33 or placebo in 68 patients with binge eating disorder... ...


  • Report problem


Do you like this article?


Post a comment:


Source:
http://www.medicalnewstoday.com/releases/230751.php

This article was readed 422 time/s



Same article in German:




Same article in French:




Same article in Italian:




Same article in Swedish:




Same article in Spanish:





Tags: health, news, designed, assess, week, controlled, double, blind, safety, efficacy, patients, with, or, administration, daily, oral, Alkermes, randomized, announced, topline, today, NASDAQ, Inc, results, phase, clinical, treatment, eating, placebo, binge, disorder, study, ALKS

Other news from category " Eating Disorders"